Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Uveal Melanoma × entinostat × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 6 Carcinoma, Non-Small-Cell Lung 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Melanoma 2 Carcinoma, Renal Cell 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Lymphoma 1 Lung Neoplasms 1 Hodgkin Disease 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Breast Neoplasms, Male 1

Interventions

Ipilimumab 9 pembrolizumab 6 incomplete Freund's adjuvant 6 Nivolumab 6 Dacarbazine 5 Temozolomide 4 Sunitinib 4 MART-1 Antigen 4 tebentafusp 3 sargramostim 3 montanide ISA 51 3 aflibercept 3 Paclitaxel 3 Carboplatin 3 CTLA-4 Antigen 3 Bevacizumab 3 trametinib 2 olaparib 2 lenvatinib 2 cediranib 2 Vorinostat 2 Taxes 2 Sorafenib 2 Radiosurgery 2 MAGEA3 protein, human 2 Lenalidomide 2 Interleukin-2 2 Interleukin-12 Subunit p35 2 Cyclophosphamide 2 Cisplatin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02697630 2023-12-08

PEMDAC

Vastra Gotaland Region

Phase 2 Completed

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡